Abstract
This review reconsiders evidence and strategies toward the prevention of consequential late rectal toxicity after radiation therapy, with a focus on prostate cancer. Novel clinical trial designs are encouraged, and these insights into the late effects of prostate radiation therapy have additional implications for late toxicity after cancer treatment for other tumors.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
Acknowledgments
T.N.S. is the recipient of a Clinical Investigator Team Leadership Award from the National Cancer Institute.